Sr Clinical Development Scientist (CAR-T Therapy)

Location: London, United Kingdom

Company

hirify.global is a biopharmaceutical company developing cancer immunotherapies, including CAR and TCR-engineered cell therapies designed to help the immune system recognize and eliminate tumors.

What you will do

• Support late-stage oncology clinical development in collaboration with the Clinical Scientist Program Lead.
• Contribute to clinical study start-up, execution, close-out, and program implementation activities.
• Develop study concept sheets, protocols, amendments, study manuals, and Investigator meeting materials.
• Support the design of case report forms, data management manuals, and data analysis plans.
• Review data listings, summary tables, study results, manuscripts, scientific presentations, and regulatory documents.
• Address scientific and procedural questions, anticipate study obstacles, coordinate teams, and provide clinical monitoring when required.

Requirements

• PharmD or PhD in clinical research or clinical pharmacology with scientific or drug development experience, or an MS with 6+ years or BS/RN with 8+ years of relevant experience.
• Experience in biopharmaceutical, healthcare, consulting, academic, or related environments.
• Understanding of drug development phases and clinical trials across phases.
• Knowledge of FDA and EMA regulations, ICH guidelines, Good Clinical Practice, and standard clinical procedures.
• Strong analytical, communication, organizational, learning, flexibility, and adaptability skills.
• Experience with Microsoft Office and other job-related programs.

Nice to have

• Experience with multiple myeloma or CAR-T therapy.

Culture & Benefits

• Full-time employment.
• Work in a mission-driven biopharmaceutical environment focused on cancer therapies.
• Inclusive culture focused on employee development, empowerment, and strong people leadership.
• Work according to regulatory requirements, industry Good Clinical Practice standards, and Gilead standard operating procedures.